Gilead Sciences announces retirement of chief operating officer

Gilead Sciences has announced that Kevin Young, its chief operating officer, will be leaving the company early in 2018.

Mr Young has been with the company since 2004 and has led its worldwide commercial operations for a number of years, overseeing the introduction of multiple new products, including the first single-tablet regimens for HIV and the first oral direct-acting antiviral regimens for chronic hepatitis C.

He previously retired from his full-time role in 2014 and served as a senior advisor to Gilead until 2016, when he returned to the chief operating officer role. Prior to Gilead, he spent more than 20 years working for companies such as ICI Pharmaceuticals and Amgen.

Having confirmed his exit from the company, Mr Young will remain with Gilead throughout the first quarter of next year and in an advisory capacity thereafter.

Dr John Milligan, president and chief executive officer of Gilead Sciences, said: "I am delighted that he will be helping us manage through a period of change over the next several months and I am deeply grateful to Kevin for his contributions to Gilead."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.